Carol, an oncology nurse and grandmother was diagnosed with Ductal Carcinoma in Situ (DCIS) or stage 0 breast cancer in 2012. Knowing that she did not want to undergo radiation treatment unless it was confirmed that this treatment was warranted based on her risks of recurrent disease, Carol discussed her treatment options with her surgical oncologist, medical oncologist, and radiation oncologist, and it was determined there was only one way to proceed. The Oncotype DX test for DCIS. She, along with her group of doctors, knew that Oncotype DX would help determine her individual need for radiation. The test would also help her understand her risk of recurrence. The results came in and confirmed that Carol could substantially reduce her risk of future recurrence from radiation treatments, which she proceeded to do.
“The test ultimately empowered me to make the best treatment decision for my cancer.”
"Throughout my treatment journey, most important were my physicians, who were aware of the value that the Oncotype DX test could provide, my friends, my peers, and most of all, my family. The test ultimately empowered me to make the best treatment decision for my cancer."
Carol is happy to have received personalized care, and she understands that she made the right decision for her and the people she loves. Throughout her treatment, Carol was able to continue to work part-time as an Oncology Nurse and felt like she could fully relate to her patients after her own experience with DCIS.